Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use

Clicks: 10
ID: 337583
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #435 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) can occur in individuals who are not overweight or have obesity (normal-BMI MASLD), yet disease burden and management remain poorly characterized. We compared long-term outcomes and incretin-based therapy use between normal-BMI MASLD (nbMASLD) and overweight/obesity-associated MASLD (obMASLD) across racial and ethnic groups. METHODS: We conducted a retrospective, observational study using the TriNetX United States Network. Adults diagnosed with MASLD or metabolic dysfunction-associated steatohepatitis (MASH) from 2005-2025 were classified using ethnicity-informed normal-BMI thresholds: <23 kg/m2 for Asian, <27 kg/m2 for Native Hawaiian and Pacific Islander, and <25 kg/m2 for White/others. Propensity-score matching balanced demographic and clinical covariates. Outcomes were assessed using Kaplan-Meier analyses and Cox proportional hazards models with obMASLD as the reference group. RESULTS: Among 619,171 eligible patients, 51,940 matched pairs were identified. Nb-BMI MASLD was associated with higher all-cause mortality across grouped ethnic groups, with survival of 77.49% versus 83.93% in obMASLD (HR 1.735, CI 1.653-1.822). Ethnicity-specific risks included higher myocardial infarction risk in White and Black patients, higher stroke risk in White patients, higher ESRD risk in Black patients, and increased cancers (colorectal, pancreatic and multiple myeloma) among White patients. Incretin-based therapy (IBT) use was markedly lower in nbMASLD but was associated with improved survival. CONCLUSIONS: Patients with nbMASLD demonstrated an increased mortality and ethnicity-specific clinical complications than obMASLD despite a more favorable metabolic profile. These findings demonstrate a potential treatment gap for nbMASLD patients and the shortcomings of BMI-based strategies to risk-stratify MASLD patients.
Reference Key
openalex_W7221376955 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Isabel Casimiro, Aoi Agawa, Rachel Haide Naraval Tacata, Eunjung Lim, Scott K. Kuwada
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag439
URL
https://doi.org/10.1210/clinem/dgag439
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.